Estrategias terapéuticas del cáncer de próstata de estadio T3

Greene, 2002 Bostwick, 2003, Contemporary pathology of prostate cancer, Urol. Clin. N. Am., 30, 181, 10.1016/S0094-0143(02)00189-1 Sakr, 1996, Staging and reporting of prostate cancer-sampling of the radical prostatectomy specimen, Cancer, 78, 366, 10.1002/(SICI)1097-0142(19960715)78:2<366::AID-CNCR29>3.0.CO;2-T O'Dowd, 1997, Update on the appropriate staging evaluation for newly diagnosed prostate cancer, J. Urol., 158, 687, 10.1016/S0022-5347(01)64295-2 Standards, 2002 Bolla, 1999, Management strategies for patients with locally advanced prostate cancer, 329 Cooperberg, 2003, Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE), J. Urol., 171, 21 Jemal, 2005, Cancer statistics, 2005, CA Cancer J. Clin., 55, 10, 10.3322/canjclin.55.1.10 Mettlin, 1998, The national cancer data base report on prostate carcinoma after the peak in incidences rates in the US, Cancer, 83, 1679, 10.1002/(SICI)1097-0142(19981015)83:8<1679::AID-CNCR24>3.0.CO;2-Y Peneau, 1998, Cancer de prostate de stade T3 clinique : histoire naturelle, les choix thérapeutiques et leurs résultats, Prog. Urol., 8, 977 Moskovitz, 1987, Cancer of the prostate, is there a need for aggressive treatment?, Urol. Int., 42, 49, 10.1159/000281849 George, 1988, Natural history of localized prostatic cancer, Lancet, 1, 494, 10.1016/S0140-6736(88)91294-9 Adolfsson, 1993, Deferred treatment of low grade stage T3 prostate cancer without distant metastases, J. Urol., 14, 326, 10.1016/S0022-5347(17)36071-8 Kojima, 1998, Influence of noncancerous prostatic tissue volume on prostate-specific antigen, Urology, 51, 293, 10.1016/S0090-4295(97)00497-4 Noldus, 1996, Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients, J. Urol., 155, 232, 10.1016/S0022-5347(01)66602-3 Cho, 1998, Diffuse prostatic lesions: role of color Doppler and power Doppler ultrasonography, J. Ultrasound Med., 17, 283, 10.7863/jum.1998.17.5.283 Cornud, 1996, Local staging of prostate cancer by endorectal MRI using fast spin-echo sequences: prospective correlation with pathological findings after radical prostatectomy, Br. J. Urol., 77, 843, 10.1046/j.1464-410X.1996.01313.x Hamper, 1990, Bright echogenic foci in early prostatic carcinoma: sonographic and pathologic correlation, Radiology, 176, 339, 10.1148/radiology.176.2.2195587 Cornud, 1992, What may be expected from endorectal echography and magnetic resonance imaging in the evaluation of local extension of cancer of the prostate?, J. Radiol., 73, 617 Ravery, 1994, Systematic biopsies accurately predict extra-capsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy, Urology, 44, 371, 10.1016/S0090-4295(94)80095-2 Dietrick, 1995, Core cancer length in ultrasound-guided systematic sextant biopsies: a prospective evaluation of prostate cancer volume, Urology, 45, 987, 10.1016/S0090-4295(99)80119-8 Ravery, 1996, Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1-T2 prostate carcinoma?, Cancer, 78, 1079, 10.1002/(SICI)1097-0142(19960901)78:5<1079::AID-CNCR18>3.0.CO;2-# Bostwick, 1996, Prediction of capsular perforation and seminal vesicle invasion in prostate cancer, J. Urol., 155, 1361, 10.1016/S0022-5347(01)66267-0 Huland, 1996, Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies, J. Urol., 155, 1344, 10.1016/S0022-5347(01)66262-1 Narayan, 1995, The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer, Urology, 46, 205, 10.1016/S0090-4295(99)80195-2 Partin, 1997, Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update, JAMA, 277, 1445, 10.1001/jama.1997.03540420041027 Partin, 2001, Contemporary update of prostate cancer staging nomograms for the new millennium, Urology, 58, 843, 10.1016/S0090-4295(01)01441-8 Ross, 2002, Comparisons of nomograms and urologists' predictions in prostate cancer, Semin. Urol. Oncol., 20, 82, 10.1053/suro.2002.32490 Wheeler, 1998, Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer, Hum. Pathol., 29, 856, 10.1016/S0046-8177(98)90457-9 Epstein, 1996, Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up, Am. J. Surg. Pathol., 20, 286, 10.1097/00000478-199603000-00004 McNeal, 1990, Capsular penetration in prostate cancer. Significance for natural history and treatment, Am. J. Surg. Pathol., 14, 240, 10.1097/00000478-199003000-00005 Epstein, 1996, Incidence and significance of positive margins in radical prostatectomy specimens, Urol. Clin. North Am., 23, 651, 10.1016/S0094-0143(05)70343-8 Pound, 1997, Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control, Urol. Clin. North Am., 24, 395, 10.1016/S0094-0143(05)70386-4 Lowe, 1997, Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patients for adjuvant therapy, J. Urol., 158, 1452, 10.1016/S0022-5347(01)64240-X Cornud, 2006, MRI and staging evaluation of prostate cancer, J. Radiol., 87, 228, 10.1016/S0221-0363(06)73997-X Coakley, 2003, Magnetic resonance imaging and spectroscopic imaging of prostate cancer, J. Urol., 170, 69, 10.1097/01.ju.0000094958.23276.c4 Taouli, 2006, MR spectroscopic imaging for evaluation of prostate cancer, J. Radiol., 87, 222, 10.1016/S0221-0363(06)73996-8 Descotes, 2003, Urology imaging: contribution of imaging in prostatic cancer, Prog. Urol., 13, 843 Peneau, 2004, Indications for pelvic lymphadenectomy in clinically localized prostate cancer, Prog. Urol., 14, 287 Burkhard, 2004, The role of lymphadenectomy in prostate cancer, Urol. Oncol., 22, 198, 10.1016/j.urolonc.2004.04.032 Heidenreich, 2003, Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis, J. Urol., 169, 1090, 10.1097/01.ju.0000047517.49221.ac Bader, 2003, Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?, J. Urol., 169, 849, 10.1097/01.ju.0000049032.38743.c7 Messing, 1999, Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer, N. Engl. J. Med., 341, 1781, 10.1056/NEJM199912093412401 Waroschek, 2003, Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases, Urol. Int., 70, 303, 10.1159/000070140 Soulie, 2004, Cancer de la prostate. Recommandations CCAFU 2004, Prog. Urol., 14, 913 Pollack, 2000, Preliminary results of a randomised radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer, J. Clin. Oncol., 18, 3904, 10.1200/JCO.2000.18.23.3904 D'Amico, 2004, 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial, JAMA, 292, 821, 10.1001/jama.292.7.821 Bolla, 2002, Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial, Lancet, 360, 103, 10.1016/S0140-6736(02)09408-4 Pilepich, 2001, Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate, Int. J. Radiat. Oncol. Biol. Phys., 50, 1243, 10.1016/S0360-3016(01)01579-6 1997, Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel, Int. J. Radiat. Oncol. Biol. Phys., 37, 1035 Lawton, 2001, Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standart radiation therapy for unfavourable prognosis carcinoma of the prostate, Int. J. Radiat. Oncol. Biol. Phys., 49, 937, 10.1016/S0360-3016(00)01516-9 McLeod, 2005, Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer, BJU Int., 97, 247, 10.1111/j.1464-410X.2005.06051.x Valicenti, 2003, RTOG 94–06: Is the addition of neoadjuvant hormonal therapy to dose escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?, Int. J. Radiat. Oncol. Biol. Phys., 57, 614, 10.1016/S0360-3016(03)00640-0 Van Den Ouden, 1998, Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy, J. Urol., 160, 1392, 10.1016/S0022-5347(01)62546-1 Van Poppel, 2000, Radical prostatectomy can provide cure for well selected clinical stage T3 prostate cancer, Eur. Urol., 38, 372, 10.1159/000020311 Ghavamian, 1999, Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTx Nx prostate cancer: a matched comparison, J. Urol., 161, 1223, 10.1016/S0022-5347(01)61640-9 Messing, 1999, Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer, N. Engl. J. Med., 341, 1781, 10.1056/NEJM199912093412401 Schmid, 1997, Impact of minimal lymph node metastasis on long-term prognosis after radical prostatectomy, Eur. Urol., 31, 11, 10.1159/000474411 Grossfeld, 2003, Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer, J. Urol., 169, 157, 10.1016/S0022-5347(05)64058-X Berglund, 2006, Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis, Urology, 67, 1253, 10.1016/j.urology.2005.12.003 Ward, 2005, Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome, BJU Int., 95, 751, 10.1111/j.1464-410X.2005.05394.x Schulman, 2000, Four-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0MO prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer, Eur. Urol., 38, 706, 10.1159/000020366 Scolieri, 2000, Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?, J. Urol., 164, 1465, 10.1016/S0022-5347(05)67008-5 Yu, 1997, Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis, Radiology, 202, 697, 10.1148/radiology.202.3.9051019 Staerman, 2006, Prise en charge des marges positives après prostatectomie totale pour cancer localisé de la prostate, Prog. Urol., 16, 286 Blute, 1998, Pathologic classification of prostate carcinoma: the impact of margin status, Cancer, 82, 902, 10.1002/(SICI)1097-0142(19980301)82:5<902::AID-CNCR15>3.0.CO;2-4 Fesseha, 1997, Pronostic implications of a positive apical margin in radical prostatectomy specimens, J. Urol., 158, 2176, 10.1016/S0022-5347(01)68189-8 Obek, 1999, Positive surgical margins with radical retropubic prostatectomy: anatomic side-specific pathologic analysis and impact on prognosis, Urology, 54, 682, 10.1016/S0090-4295(99)00204-6 Ohori, 1995, Prognostic significance of positive surgical margins in radical prostatectomy specimen, J. Urol., 154, 1818, 10.1016/S0022-5347(01)66792-2 Stamey, 1999, Biological determinants of cancer progression in men with prostate cancer, JAMA, 281, 1395, 10.1001/jama.281.15.1395 Bolla, 2004, Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostate cancer (PC)? (EORTC 22911), J. Clin. Oncol., 22, 4504, 10.1200/jco.2004.22.14_suppl.4504 Meier, 1992, Postoperative radiation therapy after radical prostatectomy for prostate carcinoma, Cancer, 70, 1960, 10.1002/1097-0142(19921001)70:7<1960::AID-CNCR2820700725>3.0.CO;2-W Paulson, 1990, Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule, J. Urol., 143, 1178, 10.1016/S0022-5347(17)40219-9 Messing, 2004, Immediate hormonal therapy versus observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer: at 10 years results of EST 3886, Proc. Am. Sos Clin. Oncol., 23, 4570, 10.1200/jco.2004.22.14_suppl.4570 Corn, 1999, Does androgen suppression enhance the efficacy of post-operative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group, Urology, 54, 495, 10.1016/S0090-4295(99)00186-7 Beuzeboc, 2006, Traitements adjuvants du cancer de prostate localisé, Reflex Med. Oncol., 10, 17 Aus, 2001, EAU guidelines on prostate cancer, Eur. Urol., 40, 97, 10.1159/000049758 Aus, 1995, Long-term survival and mortality in prostate cancer treated with noncurative intent, J. Urol., 154, 460, 10.1016/S0022-5347(01)67074-5 Meng, 2002, Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer, Urology, 60, 7, 10.1016/S0090-4295(02)01560-1 1997, Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial, Br. J. Urol., 79, 235, 10.1046/j.1464-410X.1997.d01-6840.x 2000, Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials, Lancet, 355, 1491, 10.1016/S0140-6736(00)02163-2 Samson, 2002, Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma, Cancer, 95, 361, 10.1002/cncr.10647 Eisenberger, 1998, Bilateral orchiectomy with or without flutamide for metastatic prostate cancer, N. Engl. J. Med., 339, 1036, 10.1056/NEJM199810083391504 Boccon-Gibod, 2003, Management of locally advanced prostate cancer: a European consensus, Int. J. Clin. Pract., 57, 187 See, 2002, Biculamide as immediate therapy either alone or as adjuvant to standart care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program, J. Urol., 168, 429, 10.1016/S0022-5347(05)64652-6 Walsh, 2001, A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment, J. Urol., 166, 508, 10.1016/S0022-5347(05)65972-1